Pralsetinib

Pralsetinib, sold under the brand name Gavreto, is a medication for the treatment of metastatic RET fusion-positive non-small cell lung cancer. Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth. The most common adverse reactions include increased aspartate aminotransferase, decreased hemoglobin, decreased lymphocytes, decreased neutrophils, increased alanine aminotransferase, increased creatinine, increased alkaline phosphatase, fatigue, constipation, musculoskeletal pain, decreased calcium, hypertension, decreased sodium, decreased phosphate, and decreased platelets. Pralsetinib was approved for medical use in the United States in September 2020.